Taysha Gene Therapies (NASDAQ:TSHA) Price Target Raised to $12.00 at Robert W. Baird

Key Points

• Analysts at Robert W. Baird have raised the price target for Taysha Gene Therapies from $7.00 to $12.00, indicating a potential upside of 152.84% from its current price.
• The stock is currently rated as a "buy" by nine analysts, with an average consensus price target of $9.00.
• Taysha Gene Therapies reported a revenue of $1.99 million for the quarter, surpassing analysts' expectations of $1.61 million, despite a loss in earnings per share.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) had its target price raised by analysts at Robert W. Baird from $7.00 to $12.00 in a report issued on Thursday,Benzinga reports. The brokerage currently has an "outperform" rating on the stock. Robert W. Baird's target price suggests a potential upside of 152.84% from the stock's current price.

A number of other equities research analysts have also recently issued reports on the stock. Chardan Capital boosted their target price on shares of Taysha Gene Therapies from $9.00 to $10.00 and gave the company a "buy" rating in a report on Tuesday, August 12th. Wells Fargo & Company increased their price objective on Taysha Gene Therapies from $7.50 to $8.00 and gave the stock an "overweight" rating in a report on Wednesday, August 13th. Bank of America initiated coverage on Taysha Gene Therapies in a research note on Friday, July 11th. They issued a "buy" rating and a $8.00 target price for the company. Finally, Needham & Company LLC upped their price target on Taysha Gene Therapies from $8.00 to $10.00 and gave the company a "buy" rating in a research report on Thursday. Nine analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Taysha Gene Therapies has an average rating of "Buy" and a consensus price target of $9.00.

Taysha Gene Therapies Stock Performance

Shares of Taysha Gene Therapies stock traded up $1.57 during trading hours on Thursday, hitting $4.75. 109,511,759 shares of the company's stock traded hands, compared to its average volume of 3,648,458. The stock has a market capitalization of $1.29 billion, a price-to-earnings ratio of -13.96 and a beta of 0.99. Taysha Gene Therapies has a 12-month low of $1.05 and a 12-month high of $4.89. The company has a debt-to-equity ratio of 0.17, a current ratio of 12.48 and a quick ratio of 12.48. The company has a fifty day simple moving average of $2.94 and a 200-day simple moving average of $2.43.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last released its earnings results on Tuesday, August 12th. The company reported ($0.09) earnings per share for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.02). Taysha Gene Therapies had a negative net margin of 1,144.97% and a negative return on equity of 78.44%. The company had revenue of $1.99 million during the quarter, compared to analysts' expectations of $1.61 million. Equities research analysts anticipate that Taysha Gene Therapies will post -0.35 EPS for the current fiscal year.

Insider Buying and Selling at Taysha Gene Therapies

In related news, insider Sukumar Nagendran sold 200,000 shares of Taysha Gene Therapies stock in a transaction on Wednesday, September 10th. The shares were sold at an average price of $3.23, for a total value of $646,000.00. Following the sale, the insider owned 1,006,439 shares of the company's stock, valued at approximately $3,250,797.97. This trade represents a 16.58% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 3.78% of the company's stock.

Institutional Trading of Taysha Gene Therapies

Several hedge funds have recently made changes to their positions in the business. Marex Group plc acquired a new stake in shares of Taysha Gene Therapies during the 2nd quarter worth about $29,000. E Fund Management Co. Ltd. acquired a new position in Taysha Gene Therapies in the second quarter valued at $31,000. May Hill Capital LLC purchased a new position in Taysha Gene Therapies in the second quarter valued at approximately $37,000. Tower Research Capital LLC TRC raised its holdings in shares of Taysha Gene Therapies by 156.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 17,606 shares of the company's stock valued at $41,000 after buying an additional 10,742 shares during the period. Finally, BNP Paribas Financial Markets boosted its stake in shares of Taysha Gene Therapies by 51.9% in the second quarter. BNP Paribas Financial Markets now owns 18,591 shares of the company's stock valued at $43,000 after purchasing an additional 6,350 shares during the period. Institutional investors and hedge funds own 77.70% of the company's stock.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.